[go: up one dir, main page]

MX2015011945A - Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero. - Google Patents

Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.

Info

Publication number
MX2015011945A
MX2015011945A MX2015011945A MX2015011945A MX2015011945A MX 2015011945 A MX2015011945 A MX 2015011945A MX 2015011945 A MX2015011945 A MX 2015011945A MX 2015011945 A MX2015011945 A MX 2015011945A MX 2015011945 A MX2015011945 A MX 2015011945A
Authority
MX
Mexico
Prior art keywords
mrna
messenger rna
quantitative assessment
complex
specific binding
Prior art date
Application number
MX2015011945A
Other languages
English (en)
Inventor
Michael Heartlein
Frank Derosa
Anusha Dias
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MX2015011945A publication Critical patent/MX2015011945A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

La presente invención proporciona, entre otros, métodos para cuantificar la eficacia de la formación de casquetes de ARNm, particularmente ARNm sintetizado in Vitro; en algunas modalidades, los métodos de acuerdo con la presente invención comprenden proporcionar una muestra de ARNm que contiene ARNm con casquete y sin casquete, proporcionar una sustancia de unión específica al casquete en condiciones que permiten la formación de un complejo entre la sustancia de unión específica al casquete y el ARNm con casquete; y determinar cuantitativamente la cantidad del complejo en comparación con un control, y cuantificar de ese modo la eficacia de la formación de casquetes de ARNm.
MX2015011945A 2013-03-14 2014-03-14 Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero. MX2015011945A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784253P 2013-03-14 2013-03-14
PCT/US2014/027602 WO2014152673A1 (en) 2013-03-14 2014-03-14 Quantitative assessment for cap efficiency of messenger rna

Publications (1)

Publication Number Publication Date
MX2015011945A true MX2015011945A (es) 2015-12-01

Family

ID=50625146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011945A MX2015011945A (es) 2013-03-14 2014-03-14 Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.

Country Status (15)

Country Link
US (4) US10626439B2 (es)
EP (2) EP3495505B1 (es)
JP (1) JP2016515216A (es)
CN (1) CN105209633A (es)
AU (1) AU2014239264A1 (es)
BR (1) BR112015022141A2 (es)
CA (1) CA2903488A1 (es)
DK (1) DK2971098T3 (es)
EA (1) EA201591286A1 (es)
ES (2) ES2708562T3 (es)
HU (1) HUE069140T2 (es)
MX (1) MX2015011945A (es)
PL (1) PL3495505T3 (es)
TR (1) TR201901396T4 (es)
WO (1) WO2014152673A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12458604B2 (en) 2020-10-14 2025-11-04 The Trustees Of The University Of Pennsylvania Methods of lipid nanoparticle manufacture and compositions derived therefrom

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2666559T3 (es) 2009-12-01 2018-05-07 Translate Bio, Inc. Entrega del mrna para la aumentación de proteínas y enzimas en enfermedades genéticas humanas
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
ES2663360T3 (es) 2011-06-08 2018-04-12 Translate Bio, Inc. Lípidos escindibles
BR112013031553A2 (pt) 2011-06-08 2020-11-10 Shire Human Genetic Therapies, Inc. composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
EP3495505B1 (en) 2013-03-14 2024-09-11 Translate Bio, Inc. Quantitative assessment for cap efficiency of messenger rna
WO2014153052A2 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Cftr mrna compositions and related methods and uses
EP4446413A3 (en) 2013-03-14 2024-12-18 Translate Bio, Inc. Methods for purification of messenger rna
CA2903487A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger rna
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
CN105658242A (zh) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 用于苯丙酮尿症的mrna疗法
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
CN106164248B (zh) 2014-04-25 2019-10-15 川斯勒佰尔公司 信使rna的纯化方法
EP3157573A4 (en) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
EP3169335B8 (en) 2014-07-16 2019-10-09 ModernaTX, Inc. Circular polynucleotides
SE539096C2 (en) * 2015-03-18 2017-04-04 C Conjunction Ab A method, system and software application for providing context based commercial information
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
AU2016324463B2 (en) 2015-09-17 2022-10-27 Modernatx, Inc. Polynucleotides containing a stabilizing tail region
LT4104687T (lt) 2015-09-21 2024-02-26 Trilink Biotechnologies, Llc Kompozicijos ir būdai, skirti 5'-kepurę turinčių rnr sintetinimui
WO2017066573A1 (en) 2015-10-14 2017-04-20 Shire Human Genetic Therapies, Inc. Modification of rna-related enzymes for enhanced production
EP3362460A1 (en) * 2015-10-16 2018-08-22 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
WO2017066797A1 (en) * 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
US20210108252A1 (en) * 2015-12-09 2021-04-15 Novartis Ag Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
US20190167811A1 (en) 2016-04-13 2019-06-06 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
SG11201809381XA (en) 2016-05-18 2018-12-28 Modernatx Inc Polynucleotides encoding interleukin-12 (il12) and uses thereof
US12385034B2 (en) 2016-06-24 2025-08-12 Modernatx, Inc. Methods and apparatus for filtration
GB201615233D0 (en) * 2016-09-08 2016-10-26 Bbi Solutions Oem Ltd Solid Phase Conjugate
HUE059594T2 (hu) 2017-02-27 2022-11-28 Translate Bio Inc Hírvivõ RNS tisztítására szolgáló eljárások
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
EP3971291A1 (en) 2017-02-27 2022-03-23 Translate Bio, Inc. Methods for purification of messenger rna
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
WO2018231990A2 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US10034951B1 (en) 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
WO2019005540A1 (en) * 2017-06-30 2019-01-03 Codexis, Inc. T7 POLYMERASE RNA VARIANTS
WO2019005539A1 (en) 2017-06-30 2019-01-03 Codexis, Inc. T7 POLYMERASE RNA VARIANTS
JP7511344B2 (ja) 2018-04-20 2024-07-05 イルミナ インコーポレイテッド 単一細胞を封入する方法、封入された細胞およびその使用
KR20210060480A (ko) 2018-08-24 2021-05-26 트랜슬레이트 바이오 인코포레이티드 전령 rna의 정제 방법
US11072808B2 (en) 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
AU2019355177A1 (en) 2018-10-04 2021-05-06 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
AU2019364545B2 (en) 2018-10-26 2025-09-04 Illumina, Inc. Modulating polymer beads for DNA processing
WO2020097509A1 (en) 2018-11-08 2020-05-14 Translate Bio, Inc. Methods and compositions for messenger rna purification
CA3120647A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
US20220040281A1 (en) 2018-12-21 2022-02-10 Curevac Ag Rna for malaria vaccines
SG11202106666UA (en) 2018-12-21 2021-07-29 Curevac Ag Methods for rna analysis
CA3139679A1 (en) 2019-05-15 2020-11-19 Translate Bio, Inc. Methods for purification of messenger rna
EP3986452A1 (en) 2019-06-18 2022-04-27 CureVac AG Rotavirus mrna vaccine
KR20220047319A (ko) 2019-08-14 2022-04-15 큐어백 아게 감소된 면역자극 특성을 갖는 rna 조합물 및 조성물
CN112626177A (zh) * 2019-10-09 2021-04-09 华中科技大学 一种快速定量检测rna加帽效率的方法
AU2021216658A1 (en) 2020-02-04 2022-06-23 CureVac SE Coronavirus vaccine
BR112022024248A2 (pt) 2020-05-29 2023-10-10 CureVac SE Vacinas de combinação à base de ácido nucleico
CA3187138A1 (en) * 2020-06-26 2021-12-30 Carisma Therapeutics Inc. Mrna transfection of immune cells
US20230272052A1 (en) 2020-07-31 2023-08-31 CureVac SE Nucleic acid encoded antibody mixtures
CN113278666A (zh) * 2020-08-20 2021-08-20 深圳市瑞吉生物科技有限公司 一种Cap2结构5′帽子类似物及其制备方法和应用
CA3170743A1 (en) 2020-08-31 2022-03-03 Susanne RAUCH Multivalent nucleic acid based coronavirus vaccines
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
WO2022135993A2 (en) 2020-12-22 2022-06-30 Curevac Ag Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
CA3170747A1 (en) 2021-01-27 2022-08-04 Moritz THRAN Method of reducing the immunostimulatory properties of in vitro transcribed rna
MX2023011400A (es) 2021-03-26 2023-10-09 Glaxosmithkline Biologicals Sa Composiciones inmunogenicas.
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
EP4351777A4 (en) * 2021-06-07 2025-04-16 The University of Massachusetts Apparatus and method for the continuous production of RNA
US20240398933A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
EP4416304A4 (en) * 2021-10-14 2025-08-27 Indevr Inc NUCLEIC ACID ARRAYS FOR MRNA CHARACTERIZATION
CA3206012A1 (en) 2022-02-28 2023-08-28 Guangzhou Henovcom Bioscience Co., Ltd. Compounds for rna capping and uses thereof
CN115260264B (zh) * 2022-02-28 2023-06-09 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
US20240240236A1 (en) * 2022-04-15 2024-07-18 Thermo Finnigan Llc Method for quantitative monitoring mrna capping efficiency
CN115896239A (zh) * 2022-07-25 2023-04-04 四川康德赛医疗科技有限公司 一种rna修饰效率的定量方法、试剂盒及其应用
AU2023353931A1 (en) 2022-09-26 2025-03-20 Glaxosmithkline Biologicals Sa Influenza virus vaccines
DE202023106198U1 (de) 2022-10-28 2024-03-21 CureVac SE Impfstoff auf Nukleinsäurebasis
EP4658809A1 (en) * 2023-01-31 2025-12-10 Seqirus Inc. Capping assay
EP4658239A1 (en) 2023-02-03 2025-12-10 GlaxoSmithKline Biologicals S.A. Rna formulation
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
WO2024223728A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
CN116640833B (zh) * 2023-06-01 2024-11-26 中国医学科学院医学生物学研究所 一种利用毛细管电泳技术自动化批量检测mRNA加帽率的方法
CN116426610B (zh) * 2023-06-08 2024-01-05 启辰生生物科技(珠海)有限公司 一种LC-MS法准确定量mRNA加帽效率的方法
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3529478A1 (de) 1985-08-16 1987-02-19 Boehringer Mannheim Gmbh 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
ATE149841T1 (de) 1990-01-26 1997-03-15 Immunomedics Inc Impfstoffe gegen krebs und infektionskrankheiten
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
DE4140463A1 (de) 1991-12-09 1993-06-17 Boehringer Mannheim Gmbh 2'-desoxy-isoguanosin, dessen isostere analoge sowie anwendung derselben
US5256555A (en) 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6043060A (en) 1996-11-18 2000-03-28 Imanishi; Takeshi Nucleotide analogues
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6143877A (en) 1997-04-30 2000-11-07 Epoch Pharmaceuticals, Inc. Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in double stranded nucleic acids
NZ503765A (en) 1997-09-12 2002-04-26 Exiqon As Bi-cyclic and tri-cyclic nucleotide analogues
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
DE60031282T2 (de) 1999-08-30 2007-05-03 Roche Diagnostics Gmbh 2-azapurine verbindungen und ihre verwendung
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
EP1373874A4 (en) 2001-01-31 2004-03-31 Univ Texas METHOD AND DEVICE FOR CONFINING MATERIALS IN A MICROWORKED CHEMICAL SENSOR ARRAY
EP1527175B1 (en) * 2002-06-24 2009-05-27 Exiqon A/S Methods and systems for detection and isolation of a nucleotide sequence
CA2649325C (en) 2006-04-14 2019-01-08 Epicentre Technologies Corporation Kits and methods for generating 5' capped rna
EP2049665A2 (en) 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
US20100035249A1 (en) * 2008-08-05 2010-02-11 Kabushiki Kaisha Dnaform Rna sequencing and analysis using solid support
ES2666559T3 (es) 2009-12-01 2018-05-07 Translate Bio, Inc. Entrega del mrna para la aumentación de proteínas y enzimas en enfermedades genéticas humanas
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
CA2903487A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger rna
EP3495505B1 (en) 2013-03-14 2024-09-11 Translate Bio, Inc. Quantitative assessment for cap efficiency of messenger rna
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
KR20210021943A (ko) 2018-04-25 2021-03-02 에트리스 게엠베하 미립자 제형용 동결 방지제

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12458604B2 (en) 2020-10-14 2025-11-04 The Trustees Of The University Of Pennsylvania Methods of lipid nanoparticle manufacture and compositions derived therefrom

Also Published As

Publication number Publication date
EP2971098A1 (en) 2016-01-20
EA201591286A1 (ru) 2016-02-29
US20200318156A1 (en) 2020-10-08
EP3495505B1 (en) 2024-09-11
US10626439B2 (en) 2020-04-21
PL3495505T3 (pl) 2025-01-13
ES2708562T3 (es) 2019-04-10
CN105209633A (zh) 2015-12-30
US11104934B2 (en) 2021-08-31
BR112015022141A2 (pt) 2017-08-29
WO2014152673A1 (en) 2014-09-25
HUE069140T2 (hu) 2025-02-28
US11920182B2 (en) 2024-03-05
EP2971098B1 (en) 2018-11-21
CA2903488A1 (en) 2014-09-25
JP2016515216A (ja) 2016-05-26
EP3495505A1 (en) 2019-06-12
ES2997341T3 (en) 2025-02-17
AU2014239264A1 (en) 2015-08-27
TR201901396T4 (tr) 2019-02-21
US12421538B2 (en) 2025-09-23
US20210371900A1 (en) 2021-12-02
US20240417774A1 (en) 2024-12-19
US20160002705A1 (en) 2016-01-07
DK2971098T3 (en) 2019-02-18
EP3495505C0 (en) 2024-09-11

Similar Documents

Publication Publication Date Title
MX2015011945A (es) Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
MX2015011944A (es) Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
PH12020551028A1 (en) Methods, kits and apparatus for expanding a population of cells
GB2511221A (en) Methods and compositions for classification of samples
GB201108236D0 (en) Method
SG10201907215QA (en) Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
WO2016130704A3 (en) Methods and compositions for analyzing cellular components
MX2012004310A (es) Metodo para caracterizar almenos un microorganismo por medio de espectrometria de masa.
WO2012009644A3 (en) Methods to identify synthetic and natural rna elements that enhance protein translation
MX2017015758A (es) Componente de dispositivo, dispositivo, y metodo para purificar y ensayar biomoleculas de muestras biologicas.
GB201200658D0 (en) Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
NZ701824A (en) Aptamer-based multiplexed assays
MX2015013310A (es) Metodo y reactivo para determinar metabolitos de la vitamina d.
WO2013166338A3 (en) Cell capture system and use thereof
ZA202003408B (en) A microcapsule for detecting and/or quantitating an analyte in a sample
GB2496557A (en) Products and methods for identifying rock samples
GB201014028D0 (en) In-situ reagent
WO2013124738A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
BR112016000231A8 (pt) métodos para identificações de condições de separação com cromatografia de troca de íons e para análises de composições de polipeptídeos
PH12013500107A1 (en) A method of increasing the effect of an activated-potentiated form of an antibody
MX2015004419A (es) Deteccion de analito y determinacion de concentracion de analito mediante uso de perlas magnetizables.
WO2012145607A3 (en) Specific copy number aberrations as predictors of breast cancer
MX2016007148A (es) Metodos de ensayo de beta-glucano.
GB2503609A (en) Representation of spatial-frequency data as a map
MY182547A (en) Polymerase chain reaction detection system